Small Pharma Ltd

Small Pharma Ltd was a UK-based psychedelic biotechnology company that conducted the world's first clinical trials of DMT-assisted therapy for major depressive disorder; their lead compound SPL026 (N,N-dimethyltryptamine fumarate) delivered a short-lived ~20-minute psychedelic experience via IV or IM administration, and the Phase I/IIa program in collaboration with Imperial College London's Centre for Psychedelic Research demonstrated consistent quality of psychedelic response and antidepressant effects; the company was subsequently acquired by Cybin Inc. to create the industry's largest deuterated DMT program.